Openbookopenbook
Equity
Medicover AB Series B(0RPS)
SEK --+0.00%
Reward56Moderate
Risk57Medium-High
📊75%Data
Thin 3% profit margin · Revenue growing 10% YoY
0RPS
+0.0 · +0.00%
SEK · LSE
Medicover AB Series B |
Profitless Growth
Market Cap:27.67Bn
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
57
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0RPS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Medicover AB Series B?

Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally.

0RPS · Verdict

Solid reward · elevated risk

0RPS stands out on cash flow and growth, but watch the volatility signal.

Based on 88% data coverage

0RPS · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow71/100

    8% free-cash-flow margin

  • Growth69/100

    Rev +16.3% CAGR · earnings +87.3%

Watchouts 3

  • Volatility20/100

    Weak vs peers

  • Balance sheet24/100

    Interest covered 2.5×

  • Valuation40/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Medicover AB Series B?

Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. The company is listed on the LSE in UK, with a market capitalisation of 27.67B, and a P/E ratio of 3.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap27.67B
P/E Ratio3.4175
Dividend YieldN/A
52 Week High287.9739
52 Week Low177.7324
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding133M
No. of Employees49,409
IndustryN/A
ExchangeLSE
Beta1.554
CurrencySEK
Websitewww.medicover.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.